<DOC>
	<DOCNO>NCT00238927</DOCNO>
	<brief_summary>The purpose study determine , child age 1 6 year recurrent asthma induced upper respiratory tract infection ( URTI ) , whether administration high dos inhale fluticasone start onset symptom cold result reduce severity short duration asthma exacerbation associate reduced growth velocity , osteopenia , adrenal suppression .</brief_summary>
	<brief_title>Clinical Trial Fluticasone Versus Placebo Onset Cold Children With Asthma</brief_title>
	<detailed_description>Preschool-aged child , represent half asthmatic present pediatric emergency department acute asthma , also account hospital admission pediatric asthma . More 80 % exacerbation preschool-aged child trigger upper respiratory tract infection ( URTIs ) . Current management condition clearly unsatisfactory . In case , 24-48 hour delay first sign viral infection onset asthmatic symptom , suggest window opportunity intervention could initiate alter severity asthma exacerbation . Prior trial test chronic inhale steroid throughout viral season fail demonstrate benefit examine episodic inhaled steroid onset URTI report modest benefit duration severity symptom . The selection child mild exacerbation , small sample size , cross-over design , short study period , relatively low dos inhale steroid may limit magnitude observed benefit attributable episodic treatment . The aim multicentre double-blind parallel-group placebo-controlled randomize trial compare effectiveness high dos ( 750 ug bid ) inhale fluticasone HFA propellant versus placebo start onset viral illness attenuate severity duration URTI-induced asthma young child 12-month study period . Children age 1 6 year least 2 URTI-induced asthma moderate severity , i.e . require short course systemic steroid , previous 12 month 1 previous 6 month , inter-current symptom select inclusion . Fluticasone 250 ug placebo administer dose 3 puff BID onset viral illness 48 hour without asthma symptom maximum 10 day . This dose chosen approach efficacy systemic steroid significantly less adverse effect . Inhaled salbutamol administer bronchodilator `` need '' basis relief asthma symptom dose 2 4 puff 100 ug 4-hour interval longer . A 7-day run-in period serve ( 1 ) establish absence chronic symptom infrequent use salbutamol ( 2 ) obtain confirmation eligibility pharmacy report corticosteroid preparation dispense precede 12 month . Eligible child receive baseline measurement IgE measure atopy , varicella antibody safety parameter , include height , basal cortisol , lumbar bone density . Children randomly allocate one two treatment block 4 stratification type spacer ( mask mouthpiece ) recruitment site . Children follow every 3Â±1/2 month site investigator delegate end 12-month study period . The primary endpoint proportion URTIs group require treatment systemic corticosteroid confirm review medical record pharmacy record prescription dispense . Secondary endpoint include measure severity duration exacerbation , adjust number URTIs experience child study period . Compliance study drug use salbutamol ( important measure severity ) document Doser , device attach study inhaler record , blind mode , date number dos administer 45-day period . The safety profile examine growth velocity , basal cortisol , change lumbar bone density baseline end study period . A clinically important reduction severity duration viral-induced asthma lead trial establish low effective dose fluticasone . If adverse effect growth , bone density , adrenal function detect test dose , safety may assume low dos . An absence benefit lead abandonment frequently use treatment strategy consider alternative therapy young child URTI-induced asthma , contribute mark proportion health care spending . An upper respiratory tract infection define rhinorrhea , nasal congestion , sore throat , ear ache , without fever , last &gt; =48 hour . URTI-induced asthma define wheeze association URTI .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>( 1 ) Children age 16 year , ( 2 ) least 2 documented episode URTIinduced asthma require systemic ( i.e. , oral , intravenous , intramuscular ) corticosteroids previous 12 month 1 episode previous 6 month , ( 3 ) intercurrent symptom ( i.e. , cough , wheeze , observed dyspnea ) document least 7 day wheeze episode , ( 4 ) suspicion allergy pollen perennial allergen , ( 5 ) caregiver good understanding French English ( ) chronic disease cystic fibrosis , bronchopulmonary dysplasia , cardiac disease , kidney disease , gastrooesophageal reflux require treatment , ( b ) intake , 21 day precede randomization , inhale , nasal , oral corticosteroid , leukotriene antagonist , cromolyn , nedocromyl , ketotifen , ( c ) prior intubation asthma exacerbation .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>asthma</keyword>
	<keyword>preschool</keyword>
	<keyword>viral</keyword>
	<keyword>upper respiratory track infection</keyword>
	<keyword>fluticasone</keyword>
	<keyword>inhaled corticosteroid</keyword>
	<keyword>placebo</keyword>
	<keyword>exacerbation</keyword>
	<keyword>severity</keyword>
	<keyword>safety</keyword>
	<keyword>growth</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>adrenal function</keyword>
	<keyword>rescue beta2-agonists</keyword>
</DOC>